BETA

10 Amendments of Jiří MAŠTÁLKA related to 2018/0161(COD)

Amendment 54 #
Proposal for a regulation
Recital 7
(7) The aim of this Regulation is to ensure that manufacturers established in the Union are able to compete effectively in those third country markets where supplementary protection does not exist or has expired. It is intended to complement the efforts of the Union’s trade policy to ensure open markets for Union-based manufacturers of medicinal products. Indirectly, it is also intended to put those manufacturers in a better position to enter the Union market immediately after expiry of the relevant supplementary protection certificate, i.e. Day-1 Entry. It would also help to serve the aim of fostering access to medicines in the Union by helping to ensure a swifter entry of generic and biosimilar medicines onto the market after expiry of the relevant certificate.
2018/11/28
Committee: JURI
Amendment 61 #
Proposal for a regulation
Recital 8
(8) In those specific and limited circumstances, and in order to create a level playing field between Union-based manufacturers and third country manufacturers, it is appropriate to restrict the protection conferred byovercome the above mentioned unintended effects deriving from a supplementary protection certificate so as to allow making for the exclusive purposes of export to third countries and entry onto the Union market immediately after expiry of the relevant supplementary protection certificate, as well as any related acts strictly necessary for that making or for the actual export or that entry onto the Union market itself.
2018/11/28
Committee: JURI
Amendment 78 #
Proposal for a regulation
Recital 9
(9) That exception should cover the making of the product, including the product which corresponds to the medicinal product protected by a supplementary protection certificate protected by a supplementary protection certificate, including the making of the corresponding medicinal product, in the territory of a Member State, for the exclusive purpose of export to third countries, and/or Day-1 Entry, as well as any upstream or downstream acts by the maker or by third parties in a contractual relationship with the maker, where such acts would otherwise require the consent of the certificate-holder, and are strictly necessary for making for the purpose of export or for the actual export itself or for Day-1 Entry. For instance, such acts may include the supply and import of active ingredients for the purpose of making the corresponding medicinal product to which the product covered by the certificate corresponds, or temporary storage of the product or medicinal product, advertising for othe exclusivr activities necessary for the purpose of actually exporting to third country destinations or Day-1 Entry.
2018/11/28
Committee: JURI
Amendment 82 #
Proposal for a regulation
Recital 10
(10) The exception should not cover placing thea medicinal product made for the exclusive purpose of export and Day-1 Entry on the market in thea Member State where a supplementary protection certificate is in force, either directly or indirectly after export, nor should it cover re-importation of the medicinal product to the market of a Member State in which a certificate is in force. Moreover, it should not cover any act or activity for the purpose of import of medicinal products, or parts of medicinal products, into the Union merely for the purposes of repackaging and re-exporting.
2018/11/28
Committee: JURI
Amendment 90 #
Proposal for a regulation
Recital 11
(11) By limiting the scope of the exception to making for the purposes of Day-1 Entry and of export outside the Union and acts strictly necessary for such making or for the actual export itself, the exception introduced by this Regulation will not unreasonably conflict with normal exploitation of the product or medicinal product in the Member State where the certificate is in force, nor unreasonably prejudice the legitimate interests of the certificate-holder, taking account of the legitimate interests of third parties.
2018/11/28
Committee: JURI
Amendment 149 #
Proposal for a regulation
Recital 22
(22) This Regulation respects fundamental rights and observes the principles recognised by the Charter of Fundamental Rights of the European Union. In particular, this Regulation seeks to ensure full respect for the right to property in Article 17 of the Charter by maintaining the core rights of the supplementary protection certificate and the right to healthcare in Article 35 of the Charter, by enhancing access to medicines for all patients, by confining the exception to certificates granted on or after a specified date after entry into force of this Regulation and by imposing certain conditions on the application of the exception,
2018/11/28
Committee: JURI
Amendment 161 #
Proposal for a regulation
Article 1 – paragraph 1 – point 1
Regulation (EC) No 469/2009
Article 4 – paragraph 2 – introductory part
2. The certificate referred to in paragraph 1 shall not confer protection against a particularcertain acts against which the basic patent conferred protection if, with respect to that particular act, the following conditions are met:
2018/11/28
Committee: JURI
Amendment 166 #
Proposal for a regulation
Article 1 – paragraph 1 – point 1
Regulation (EC) No 469/2009
Article 2 – paragraph 2 – point a
(a) the acts comprises:
2018/11/28
Committee: JURI
Amendment 172 #
Proposal for a regulation
Article 1 – paragraph 1 – point 1
Regulation (EC) No 469/2009
Article 4 – paragraph 2 – point a – point i
(i) making for the exclusive purpose of export to third countries; and / or entry onto the market of Member States immediately after expiry of the certificate in those Member States, and/or
2018/11/28
Committee: JURI
Amendment 185 #
Proposal for a regulation
Article 1 – paragraph 1 – point 1
Regulation (EC) No 469/2009
Article 4 – paragraph 2 – point a – point ii
(ii) any related act that is strictly necessary for that making or for the actual export itself;export, and/or for effectively entering the market of Members States immediately after expiry of the certificate in these Members States.
2018/11/28
Committee: JURI